Trailhead Biosystems Inc., a Cleveland biotechnology company that is developing cell therapies for products that target type I diabetes, Parkinson’s disease, multiple sclerosis, Alzheimer’s disease and blood disorder, announced it has raised $6.6 million in Series A financing.
The company said in a news release that the financing will expand its High Dimensional Design of Experiments platform, support the generation of multiple specialized human cells with therapeutic properties, and enable pilot-scale manufacturing. It said “critical support” in closing the financing was provided by the Entrepreneurship & innovation Clinic at Yale Law School.
Click here to read the complete story.
Story excerpt provided by Crain’s Cleveland Business.
Written by Scott Suttell.
Originally published November 11, 2020.